论文部分内容阅读
目的观察重组人白介素-2局部注射递增疗法治疗跖疣的临床疗效。方法选取跖疣患者192例,随机分为两组,治疗组98例,采用白介素-2递增疗法治疗(1次5万U,2次10万U,10次50万U),3d局封1次,10次为一个疗程;对照组94例,采用冷冻治疗,15d冷冻1次,4次为一个疗程。通过8周的治疗得出两组间的效果差异。结果治疗组的有效率为93.88%,治愈率为87.76%,高于对照组的72.34%和64.89%;治疗组复发率为6.98%,低于对照组的31.15%;以上差异均有统计学意义(P均<0.05)。结论重组人白介素-2局部注射递增疗法治疗跖疣,治愈率高,复发率低,疗效确切。
Objective To observe the clinical efficacy of recombinant human interleukin-2 (IL-2) in the treatment of plantar warts by local injection. Methods Ninety-two patients with plantar warts were randomly divided into two groups. The treatment group (n = 98) was treated with interleukin-2 increasing therapy (50000 U for 1 time, 100000 U for 2 times and 500000 U for 10 times) Times, 10 times for a course of treatment; control group of 94 cases, using cryotherapy, 15d frozen 1 times, 4 times for a course of treatment. Eight weeks of treatment resulted in differences in efficacy between the two groups. Results The effective rate of the treatment group was 93.88%, the cure rate was 87.76%, which was higher than that of the control group (72.34% vs 64.89%). The recurrence rate of the treatment group was 6.98%, which was lower than that of the control group (31.15%). The differences were statistically significant (P <0.05). Conclusions Recombinant human interleukin-2 increases the local injection therapy for plantar warts, with high cure rate, low recurrence rate and definite curative effect.